Genentech, Inc.

Newlink Genetics Corporation

Xrad Therapeutics, Inc.

F. Hoffmann-la Roche Ag

Guosheng Wu

Po-Wai Yuen

Richard Pastor

Emily J Hanan

Marie-Gabrielle Braun

Aijun Lu

Steven T Staben

Yu Jiang

Georgette M Castanedo

Matthew Volgraf

Elisia Villemure

Paul Gibbons

Robert Andrew Heald

Lewis J Gazzard

Jacob Bradley Schwarz

Zhonghua Pei

Rohan V Mendonca

Cuong Q Ly

Joseph P Lyssikatos

Anthony A Estrada

Huifen Chen

Po-wai Yuen

Steven Huy Do

Aleksandr Kolesnikov

Shuang Zhang

Jianwen A Feng

Sharada Shenvi Labadie

Jianmin Fu

Firoz Jaipuri

Calum MacLeod

Vishal Verma

Nicole Blaquiere

Lan Wang

Jesse Waldo

Sanjeev Kumar

Jason Burch

Daniel Shore

Yun-Xing Cheng

Yue Sun

Calum Macleod

Yaode Wang

Joachim Rudolph

Peter Andrew Smith

Qiang Guo

Keira Garland

Benjamin Douglas Sellers

Baihua Hu

Xingyu Lin

Hans Purkey

Brendan Parr

Siew Kuen Yeap

Yuhong Fu

Ramsay Beveridge

Wendy Liu

Jiang Yu

Jamie Knight

Hima Potturi

Yao Wu

Yanyan Chu

Zuhui Zhang

Michael Kastan

Tona Gilmer

William Vernier

Robert Goodnow

David Kirsch

Roheeth Pavana

Xiaokai Li

Yunxing Cheng

Venkata Velvadapu

Marie Gabrielle Braun

Benjamin Sellers

Kuean Yeap Siew

Xiangqing Xu

Song Zhao

Yuanyuan Hou

Peng Jing

Yingying Dong

Quxiang Li

Minquan Yu

Yinli Qiu

Robert A Goodnow

Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of lipoprotein signal peptidase II (LspA), a key protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

Cyclic peptide antibiotics

Described herein are pyrido-pyrimidinone and pteridinone compounds or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods treating cancer, alone and in combination with other therapeutic agents.

Pyrido-pyrimidinone and pteridinone compounds and methods of use

Provided herein are compounds of the Formula (I), (II), and (III): as well as pharmaceutically acceptable salts thereof, wherein the substituents are those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of oncologic diseases.

Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy

Presently provided are inhibitors of cellularly expressed TD02 and IDO1, and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2,3 dioxygenase and indoleamine 2,3-dioxygenase 1; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer. 

TDO2 and IDO1 inhibitors

The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators

Presently provided are inhibitors of cellularly expressed TDO2 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.

TDO2 Inhibitors

The present invention relates to certain thiazolopyrimidinone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

Thiazolopyrimidinones and methods of use thereof

Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: 

Tricyclic PI3K inhibitor compounds and methods of use

The invention relates to pyridopyrimidinone compounds of formula I or pharmaceutically acceptable salts thereof, wherein X, R, R, R, R, Rand Rare as defined herein, as well as pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

Pyridopyrimidinones and methods of use thereof

The invention relates to compounds of Formula (0): 

Alkynyl alcohols and methods of use

Growing community of inventors

Beijing, China

Guosheng Wu